Updates in the Evaluation and Management of Breast Cancer

[1]  Gretchen L. Gierach,et al.  Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study , 2017, American journal of epidemiology.

[2]  H. Campbell-Enns,et al.  The psychosocial experiences of women with breast cancer across the lifespan: a systematic review , 2017, Psycho-oncology.

[3]  K. Lukong,et al.  Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants , 2017, Breast Cancer Research and Treatment.

[4]  A. Nichol,et al.  The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study. , 2017, International journal of radiation oncology, biology, physics.

[5]  Ian Krop,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Strasser,et al.  Updates in the Treatment of Breast Cancer with Radiotherapy. , 2017, Surgical oncology clinics of North America.

[7]  Christoph I. Lee,et al.  Risk-based Breast Cancer Screening: Implications of Breast Density. , 2017, The Medical clinics of North America.

[8]  J. Marsden.  Hormonal contraception and breast cancer, what more do we need to know? , 2017, Post reproductive health.

[9]  S. Loibl,et al.  HER2-positive breast cancer , 2017, The Lancet.

[10]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[11]  B. Arun,et al.  Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. , 2017, The oncologist.

[12]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[13]  Shuo Deng,et al.  Breast Cancer: Exploring the Facts and Holistic Needs during and beyond Treatment , 2017, Healthcare.

[14]  H. Gómez,et al.  Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Turnbull,et al.  Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. , 2017, Cancer treatment reviews.

[16]  S. Yao,et al.  Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer , 2017, Cancer Causes & Control.

[17]  David Cameron,et al.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial , 2017, The Lancet.

[18]  N. Harbeck,et al.  Breast cancer , 2017, The Lancet.

[19]  M. Clemons,et al.  Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Xiaoxian Li,et al.  New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. , 2017, Archives of pathology & laboratory medicine.

[21]  Ahmedin Jemal,et al.  Global Cancer in Women: Burden and Trends , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[22]  L. Pusztai,et al.  New Therapeutic Strategies for Triple-Negative Breast Cancer. , 2017, Oncology.

[23]  G. Fasola,et al.  Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. , 2017, Breast.

[24]  O. Pagani,et al.  Is it time to address survivorship in advanced breast cancer? A review article. , 2017, Breast.

[25]  W. Gradishar,et al.  Breast cancer: updates and advances in 2016 , 2017, Current opinion in obstetrics & gynecology.

[26]  M. Ellis,et al.  Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial , 2016, The Lancet.

[27]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[28]  K. Ruddy,et al.  Management of Potential Long-Term Toxicities in Breast Cancer Patients , 2016, Current Breast Cancer Reports.

[29]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[30]  M. Somerfield,et al.  Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Sinae Kim,et al.  Oncoplastic breast surgery in the setting of breast-conserving therapy: A systematic review , 2016, Advances in radiation oncology.

[32]  E. Perez,et al.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. Perez,et al.  Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[36]  S. Schnitt,et al.  Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ , 2016, Annals of Surgical Oncology.

[37]  F. Cardoso,et al.  Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. , 2016, Breast.

[38]  F. Puglisi,et al.  Do platinum salts fit all triple negative breast cancers? , 2016, Cancer treatment reviews.

[39]  J. Sparano.  A 21-Gene Expression Assay in Breast Cancer. , 2016, The New England journal of medicine.

[40]  R. Gray,et al.  Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  T. Julian,et al.  Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial , 2016, The Lancet.

[42]  J. Cuzick,et al.  Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial , 2016, The Lancet.

[43]  W. Gradishar,et al.  Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? , 2016, Oncology.

[44]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[45]  Ping Sun,et al.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. , 2015, JAMA oncology.

[46]  R. Greil,et al.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[47]  E. Perez,et al.  Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Nahabedian.  Factors to Consider in Breast Reconstruction , 2015, Women's health.

[49]  A. Nevill,et al.  Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies , 2015, Acta oncologica.

[50]  D. Cameron,et al.  Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. , 2015, The Lancet. Oncology.

[51]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[52]  H. Iwase,et al.  Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer , 2015, International Journal of Clinical Oncology.

[53]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[54]  J. Bogaerts,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[55]  S. Gomez,et al.  Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. , 2014, JAMA.

[56]  N. Lin,et al.  Updates on the management of breast cancer brain metastases. , 2014, Oncology.

[57]  K. Smith,et al.  Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer , 2014, Current Breast Cancer Reports.

[58]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[59]  A. Giobbie-Hurder,et al.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.

[60]  G. Colditz,et al.  Priorities for the primary prevention of breast cancer , 2014, CA: a cancer journal for clinicians.

[61]  R. Dienstmann,et al.  Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  A. Chagpar,et al.  Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast. , 2013, American journal of surgery.

[63]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Cath Taylor,et al.  Benefits of multidisciplinary teamwork in the management of breast cancer , 2013, Breast cancer.

[65]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[66]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[67]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[68]  C. Geyer,et al.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Baselga,et al.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  S. Schnitt,et al.  Surgical margins in lumpectomy for breast cancer--bigger is not better. , 2012, The New England journal of medicine.

[72]  L. Moja,et al.  Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.

[73]  T. Julian,et al.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[75]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[76]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[77]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. , 2011, The Lancet. Oncology.

[78]  A. Leong,et al.  The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment , 2011, Pathobiology.

[79]  J. Zujewski,et al.  Ductal carcinoma in situ: trends in treatment over time in the US , 2011, Breast Cancer Research and Treatment.

[80]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[81]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[82]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[83]  J. Cuzick,et al.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.

[84]  M. Ross,et al.  Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients , 2009, Annals of surgery.

[85]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[86]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[88]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[89]  F. Holmes,et al.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Melissa L. Johnson,et al.  Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. , 2006, Seminars in oncology.

[91]  J. Peterse,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  L. Holmberg,et al.  SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening , 2006, Acta oncologica.

[93]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[94]  L. Newman,et al.  Breast cancer in sub‐Saharan Africa: How does it relate to breast cancer in African‐American women? , 2005, Cancer.

[95]  F Puglisi,et al.  Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  Donald L. Weaver,et al.  NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial , 2004, Annals of Surgical Oncology.

[97]  J. Houghton.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial , 2003, The Lancet.

[98]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  J. Ranstam,et al.  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease , 2002, The Lancet.

[100]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[101]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[102]  N. Wolmark,et al.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. , 2001, Seminars in oncology.

[103]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[104]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[105]  H. Muss,et al.  Fluoxymesterone as Third Line Endocrine Therapy for Advanced Breast Cancer A Phase II Trial of the Piedmont Oncology Association , 1992, American journal of clinical oncology.

[106]  J. Gockerman,et al.  Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. , 1986, Cancer treatment reports.

[107]  H M Jensen,et al.  On the origin and progression of ductal carcinoma in the human breast. , 1973, Journal of the National Cancer Institute.

[108]  B. Pockaj,et al.  Intraoperative Margin Management in Breast-Conserving Surgery: A Systematic Review of the Literature , 2016, Annals of Surgical Oncology.

[109]  M. Ellis,et al.  Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. , 2016, JAMA oncology.

[110]  M. Debled,et al.  A 21-Gene Expression Assay in Breast Cancer. , 2016, The New England journal of medicine.

[111]  M. Morrow,et al.  The dilemma of DCIS. , 2007, Breast.

[112]  S. Jaffer,et al.  Chapter 9 – Pathology of Invasive Breast Cancer , 2005 .

[113]  M. Tattersall,et al.  Diethylstilbestrol revisited in advanced breast cancer management. , 1990, Medical and pediatric oncology.